NEW
YORK, Aug. 5, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that management will participate in the following
upcoming investor conferences:
- 9th Annual Needham Virtual MedTech &
Diagnostics 1x1 Conference
- Dates: August 12-13,
2024
- Canaccord Genuity 44th Annual Growth
Conference
- Fireside Chat: Tuesday, August
13, 2024, at 1:30 PM ET
The live and archived webcast of the Canaccord Genuity fireside
chat can be accessed by clicking here or by visiting the Investor
Relations Section of the Lucid Diagnostics website. A replay
of the webcast will be available on the website for 30 days
following the conclusion of the live broadcast.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and
for more information about its parent company PAVmed, please
visit www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302214081.html
SOURCE Lucid Diagnostics